New Alzheimer’s drugs from Eisai-Biogen and Eli Lilly have greater chance of approval in early 2023
Positive study results for Eisai-Biogen lifted the prospects for its medication and one from Eli Lilly—although regulators will have to weigh risks
Biogen’s Aduhelm was the first approved treatment for early stage Alzheimer’s patients that might be able to slow the disease. WSJ explains how the drug interacts with brain cells, and why some doctors aren’t ready to prescribe it. Illustration: Jacob ReynoldsAfter years of failures, drugmakers appear on the verge of rolling out two new Alzheimer’s therapies in the next several months.
The drugs, one from Eisai Co. and partner Biogen Inc. and another from Eli Lilly & Co., promise patients somea WSJ membership
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focusAn experimental Alzheimer's drug slowed cognitive decline in a trial but may carry a risk of dangerous side effects for certain patients
Read more »
Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focusThe 18-month trial enrolled nearly 1,800 participants.
Read more »
New Alzheimer’s Drug Shows Positive Results but Side EffectsA new Alzheimer’s drug slowed cognitive decline in a study, but caused brain bleeds and swelling in some patients, furthering debate about its usefulness
Read more »
Drug slows Alzheimer’s but can it make a real difference?Japanese drugmaker Eisai and its U.S. partner Biogen announced earlier this fall that lecanemab appears to work, a badly needed bright spot after disappointments in the quest for better Alzheimer's treatments.
Read more »
New Alzheimer’s drug shows promise in slowing disease but may contain significant risks, study showsAn experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers report — but it remains unclear how much difference that might make in people’s lives.
Read more »
What increasing confidence in Biogen's latest Alzheimer's drug means for Eli LillyEli Lilly's (LLY) Alzheimer's efforts are not central to our investment case, but Biogen's (BIIB) full trial data is incrementally positive.
Read more »